A deeper knowledge of the molecular mechanism of ApoA-I amyloidosis is thus required to develop effective therapeutic tools aimed at preventing fibrils accumulation, or to reduce and/or clear amyloid deposits in the affected organs. The gene discussed is APOA1; the disease is amyloidosis.